The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2020Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease
Study Rationale:
We are testing ANAVEX2-73 (also known as blarcamesine), which previous research has shown helps improve behaviors as well as normalizes biochemical changes in a Parkinson’s... -
Therapeutics Development Initiative, 2011Pharmacokinetics and Cognitive Side Effects of the Antidyskinetic Drug Fenobam in MPTP-treated Pre-clinical Models
Promising Outcomes of Original Grant:
The goal of our original project was to determine if a prodrug of acamprosate could inhibit levodopa-induced dyskinesias (LIDs) in a pre-clinical model. During... -
MJFF Research Grant, 2013Angiogenic Biomarkers in PD Dementia: Clinical-Biochemical-Pathological Correlations
Objective/Rationale:
Many patients with Parkinson´s disease (PD) eventually develop dementia, a severe form of cognitive deterioration, and widespread neurodegenerative processes affecting the...
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026Precision Mapping of Somato-Cognitive Action Network (SCAN) Pathophysiology in Parkinson’s Disease Gait Disturbance
Study Rationale:
Parkinson’s Disease (PD) is a neurodegenerative disorder caused by dysfunction in specific brain systems. We recently discovered a new brain system called the Somato-Cognitive...
-
Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022Disparities in Neurocognitive Impairment Among Hispanics and Latinos in the United States with Parkinson’s Disease: The Role of Cardiovascular Risk
Study Rationale: In the United States, Latinos with Parkinson’s disease (PD) are more likely to have problems with memory, planning and other thinking skills than individuals of other ethnic/racial...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies
Study Rationale: Forms of alpha-synuclein, the protein that aggregates in Parkinson’s disease (PD), can be detected in cerebrospinal fluid (CSF) by seed amplification assays (SAA). These highly...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.